CN119790072A - 用于刺激哺乳动物的嵌合抗原受体介导的免疫反应的方法中的针对cd123的靶向模块 - Google Patents
用于刺激哺乳动物的嵌合抗原受体介导的免疫反应的方法中的针对cd123的靶向模块 Download PDFInfo
- Publication number
- CN119790072A CN119790072A CN202380060615.0A CN202380060615A CN119790072A CN 119790072 A CN119790072 A CN 119790072A CN 202380060615 A CN202380060615 A CN 202380060615A CN 119790072 A CN119790072 A CN 119790072A
- Authority
- CN
- China
- Prior art keywords
- seq
- receptor
- targeting module
- cell
- tag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4217—Receptors for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/15—Non-antibody based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22180805.8 | 2022-06-23 | ||
| EP22180805.8A EP4296281A1 (en) | 2022-06-23 | 2022-06-23 | Targeting modules against cd123 and a tag for use in a method for stimulating a universal chimeric antigen receptor-mediated immune response in a mammal |
| EP23168260.0 | 2023-04-17 | ||
| EP23168260 | 2023-04-17 | ||
| PCT/US2023/068998 WO2023250489A1 (en) | 2022-06-23 | 2023-06-23 | Targeting modules against cd123 for use in a method for stimulating a chimeric antigen receptor-mediated immune response in a mammal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119790072A true CN119790072A (zh) | 2025-04-08 |
Family
ID=87281111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380060615.0A Pending CN119790072A (zh) | 2022-06-23 | 2023-06-23 | 用于刺激哺乳动物的嵌合抗原受体介导的免疫反应的方法中的针对cd123的靶向模块 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250269025A1 (https=) |
| EP (1) | EP4543922A1 (https=) |
| JP (1) | JP2025524457A (https=) |
| CN (1) | CN119790072A (https=) |
| AU (1) | AU2023289687A1 (https=) |
| CA (1) | CA3258275A1 (https=) |
| WO (1) | WO2023250489A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
-
2023
- 2023-06-23 AU AU2023289687A patent/AU2023289687A1/en active Pending
- 2023-06-23 WO PCT/US2023/068998 patent/WO2023250489A1/en not_active Ceased
- 2023-06-23 JP JP2024575443A patent/JP2025524457A/ja active Pending
- 2023-06-23 CN CN202380060615.0A patent/CN119790072A/zh active Pending
- 2023-06-23 CA CA3258275A patent/CA3258275A1/en active Pending
- 2023-06-23 EP EP23741575.7A patent/EP4543922A1/en active Pending
- 2023-06-23 US US18/878,321 patent/US20250269025A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250269025A1 (en) | 2025-08-28 |
| WO2023250489A1 (en) | 2023-12-28 |
| EP4543922A1 (en) | 2025-04-30 |
| JP2025524457A (ja) | 2025-07-30 |
| AU2023289687A1 (en) | 2025-01-02 |
| CA3258275A1 (en) | 2023-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108884164B (zh) | 用于免疫疗法的经修饰细胞 | |
| KR102758545B1 (ko) | Ctla-4 변이체 면역조절 단백질 및 이의 용도 | |
| CN119730875A (zh) | 包含可切换嵌合抗原细胞表面受体的工程化人t细胞及其制备方法 | |
| US20230183351A1 (en) | A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated immune response in a mammal | |
| JP2023527621A5 (https=) | ||
| US20250302875A1 (en) | TARGETING MODULES AGAINST IL13R-alpha-2 AND/OR HER2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR-MEDIATED IMMUNE RESPONSE IN A MAMMAL | |
| CN119790072A (zh) | 用于刺激哺乳动物的嵌合抗原受体介导的免疫反应的方法中的针对cd123的靶向模块 | |
| KR20240034205A (ko) | 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터 | |
| EP4566619A1 (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| EP4296281A1 (en) | Targeting modules against cd123 and a tag for use in a method for stimulating a universal chimeric antigen receptor-mediated immune response in a mammal | |
| EP4566620A1 (en) | Switchable universal chimeric antigen receptors and their use | |
| EP4382119A1 (en) | A kit for use in the treatment of hematological cancer | |
| EP4342907A1 (en) | Switchable chimeric antigen receptors and their use | |
| AU2024393901A1 (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed | |
| HK40125822A (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| HK40125821A (en) | Switchable universal chimeric antigen receptors and their use | |
| WO2024121297A1 (en) | A kit for use in the treatment of hematological cancer | |
| JP2025524457A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |